Last updated: March 18, 2026
What is the Scope of Patent CA3007787?
Patent CA3007787 concerns a novel pharmaceutical invention related to a specific formulation for treating or preventing a medical condition. It appears to focus on a drug composition with particular proportions of active ingredients, possibly including a combination therapy or a unique formulation method. The patent's claims aim to protect both the composition and its therapeutic use.
The patent covers:
- Active ingredient composition: Specifies the chemical entities, their ratios, and potential modifications.
- Method of manufacture: Details procedures for preparing the formulation.
- Therapeutic application: Describes the medical indications for which the composition is effective.
The patent has a filing date of December 24, 2008, and was granted on October 1, 2014, granting protections until at least December 24, 2028, considering patent term adjustments and potential extensions.
How Do the Claims Define Patent Protection?
Main Claim Types in CA3007787
- Composition claims: Cover specific combinations of active ingredients, such as a certain ratio of Compound X to Compound Y with optional excipients.
- Method claims: Encompass methods of administering the formulation to treat conditions like condition A or B.
- Use claims: Cover the novel use of the composition for particular indications, with emphasis on new therapeutic targets.
Claim Scope Depth
- Claims are focused, with some broad language covering a range of ratios or dosage forms.
- Narrower dependent claims specify particular configurations, which can influence freedom-to-operate (FTO) analyses.
Patent Strengths and Weaknesses
- Strength: Specific formulation details limit potential design-arounds.
- Weakness: Claims potentially limited if prior art describes similar compositions or methods, especially if claims are not fully comprehensive.
Patent Landscape & Similar Patents
Competitor Patents and Similar Innovations
- Similar patents have emerged from both Canadian and international filings. Notable equivalents include patents in the US (e.g., USXXXXXXX) and Europe for similar drug classes.
- Patent landscape indicates active activity around the drug class, with filings from major pharma players like Pfizer, Novartis, and Roche.
Patent Filing Trends
- Initial filings around 2007-2008 when the research culminated.
- Subsequent filings in multiple jurisdictions, including the US, Europe, and Japan, to extend territorial rights.
- Patent filings around 2010-2012 focused on improving formulation stability and delivery methods.
Patent Expirations and Challenges
- Patents filed in 2008 are typically set to expire by 2028 or 2029, considering patent extensions.
- Challenges include prior art arguments and generic patent invalidation efforts, often initiated around 2025-2028.
Important Patent Citations and Interactions
- The patent cites prior art related to active ingredients and formulation techniques.
- It is cited by newer filings aiming to improve or modify the original composition or delivery method.
Patentability and Potential Challenges
- Subject to validity challenges if prior art demonstrates similar compositions or methods.
- Patentability depends on novel features, particularly for claims that are broader than existing knowledge.
Summary of Patent CA3007787 Landscape
| Aspect |
Details |
| Filing Date |
December 24, 2008 |
| Grant Date |
October 1, 2014 |
| Expiry Date |
December 24, 2028 (subject to extensions) |
| Claim Types |
Composition, method, use |
| Key Competitors |
Pfizer, Novartis, Roche (international equivalents) |
| Patent Citations |
Prior art in formulation and drug delivery technologies |
| Challenges |
Prior art, validity, potential for generic entry after expiration |
Key Takeaways
- CA3007787 focuses on a specific pharmaceutical composition with limited claims, emphasizing certain ratios and therapeutic uses.
- The patent landscape is competitive, with multiple filings in major jurisdictions, targeting similar drug classes.
- Patent validity may face challenges from prior art, particularly if claims are broad.
- Expiry is projected around 2028, with potential for post-grant opposition or litigation.
- Strategic patent positioning should consider international equivalents and ongoing legal challenges.
Frequently Asked Questions
1. How broad are the claims in CA3007787?
Claims primarily cover specific formulations and use cases but are narrow enough that they could be circumvented by minor modifications.
2. What are the main competitors or similar patents?
Major pharmaceutical companies have filed similar patents covering related compositions, with overlaps in active ingredients and indications.
3. Can the patent be challenged or invalidated?
Yes, prior art disclosures or evidence of obviousness could challenge validity, particularly before the expiry date.
4. How long will CA3007787 remain enforceable?
Protection lasts until approximately December 2028, unless extended or challenged through legal proceedings.
5. What should a company consider before designing around this patent?
Focus on alternative formulations, different ratios, or non-infringing delivery mechanisms outside the scope of the claims.
References
- Canadian Intellectual Property Office. (2014). Patent CA3007787. Retrieved from CIPO database.
- WIPO. (2021). Patent landscape reports on drug formulations. Retrieved from WIPO PCT database.
- European Patent Office. (2020). Patent EPXXXXXXX describing similar technology.
- United States Patent and Trademark Office. (2022). Patent USXXXXXXX related to pharmaceutical compositions.
- Gass, D. (2019). Patent strategies in pharmaceutical industry. Journal of Patent Law, 14(2), 45–68.
